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 Introduction 
 Diabetic retinal neuropathy and optic nerve involve-
ment are frequent complications of diabetes, but they 
receive little attention in ophthalmological practice 
since diabetic retinopathy is discussed almost exclusive-
ly as vascular retinopathy (i.e. retinal involvement that 
is evident on fundoscopy) in textbooks and in the litera-
ture  [1, 2] . Vascular retinopathy, however, is mostly a 
late complication  [3] , only rarely manifest at the time of 
diagnosis  [4] . A patient diagnosed with diabetic retinop-
athy has approximately a 50% chance of losing vision in 
5 years  [3] , which in itself calls for efforts to detect reti-
nopathy at the earliest possible stage.
 Several methods have been suggested for the detec-
tion of subclinical retinopathy, such as fluorophotome-
try  [5] and various electrophysiological methods  [3, 
6–8] . Evidence suggests that the electrophysiological 
methods are sensitive and reliable indicators of the reti-
nal and optic nerve involvement in diabetes. However, 
the literature on this topic is relatively limited, and the 
significance of electrophysiological methods is clearly 
underestimated.
 In this study, the aim was to provide further evidence 
for the utility of two electrophysiological methods [vi-
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 Abstract 
 Objective: To assess the utility of visual electrophysiological 
methods, visual evoked potentials (VEPs) and pattern elec-
troretinograms (PERGs) were recorded for the detection of 
subclinical optic nerve and retinal involvement in patients 
with diabetes mellitus.  Subjects and Methods: The data of 63 
patients (126 eyes) with no vascular retinopathy or optic neu-
ropathy were retrospectively analyzed. The patients were di-
vided into polyneuropathic/nonpolyneuropathic groups to 
differentiate between early and late subclinical stages. The 
recorded parameters were compared with local reference 
values.  Results: 116 eyes (92%) had VEP and 76 (60%) had 
PERG abnormalities. The most frequent alteration was laten-
cy delay, but waveform and amplitude irregularities were 
also observed. The simultaneous use of the two methods al-
lowed us to differentiate abnormal VEPs of purely optic nerve 
origin from those reflecting retinal involvement.  Conclu-
sions: We suggest that regular electrophysiological screen-
ing should receive more attention in the ophthalmological 
care of diabetic patients.  © 2015 S. Karger AG, Basel 
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sual evoked potentials (VEPs) and pattern electroretino-
grams (PERGs)] in the detection of subclinical retinop-
athy and optic neuropathy in routine diabetes care.
 Subjects and Methods 
 In this retrospective study, data of 63 type I diabetes patients with 
no clinically manifest (vascular) retinopathy were analyzed. The pa-
tients were divided into two groups based on the presence or absence 
of polyneuropathy. Diabetic polyneuropathy was assessed with Neu-
rometer (Neurotron, Inc., Baltimore, Md., USA) and the Ewing test. 
The assessment was done by an experienced internist who routinely 
uses these methods (T.V.). Group 1 included 38 patients with poly-
neuropathy and 1–40 years of diabetes. Group 2 included 25 patients 
without polyneuropathy and also 1–40 years of diabetes.
 Exclusion criteria were any medical conditions that could in-
terfere with the electrophysiological testing, including conditions 
that affect visual acuity so that it cannot be corrected to 20/20 for 
the purposes of testing (e.g. cataract). Patients underwent VEP and 
PERG testing according to the ISCEV standards  [9, 10] . 
 Black and white checkerboard patterns were used for stimula-
tion. The check size was 60' and 15' for VEP and 48' for PERG re-
cordings. The reversal rate was 0.9 rps for VEP and 2 rps for PERG 
recordings. Filters were set between 1 and 100 rps for both VEPs 
and PERGs. The viewing distance was 1 m, and the stimulus dis-
play subtended a 12° by 16° area. The contrast was 97%. One hun-
dred responses were averaged for VEPs and 200 responses for 
PERGs. To test trial-to-trial variability, all tests were repeated in 
the same session after a break of 2 min. Monocular stimulation was 
applied for VEPs and binocular stimulation for PERGs.
 For the VEP recordings, the recording electrode (gold cup) was 
taped on the Oz site, the reference electrode on the Cz site, and the 
ground electrode on the middle of the forehead (Fz site). For the 
PERGs, DTL electrodes were used. The reference electrode (gold 
cup) was placed over either temple, approximately 1 cm from the 
ipsilateral orbital rim, and the ground electrode was placed in the 
Fz site (similarly to VEPs). For the evaluation of VEP alterations 
the N75, P100 and N135 latencies and the P100 and N135 ampli-
tudes were used. For the evaluation of PERG recordings, the N35, 
P50 and N95 peak times and the P50 and N95 amplitudes and their 
ratio (N95/P50) were calculated.
 Data from both eyes of each patient were included in the analysis, 
so as to avoid bias and misinterpretation  [11, 12] . The results were 
compared with the reference datasets of our laboratory ( tables 1,  2 ).
 For the comparisons, the Mann-Whitney U test was used, as 
the criterion of normal distribution was not met. The level of sig-
nificance was adjusted according to the Šidak correction: α 1 = 1 – 
(1 – α) 1/n where α 1 is the adjusted p level and α is the default p 
 Table 1.  Alterations of the VEP and PERG values in the polyneu-
ropathy group as compared to the reference values of the labora-
tory
Patient Reference p value
VEP
60’ N75, ms 71.42 ± 10.02 68.93 ± 5.53 0.955
15’ N75, ms 75.63 ± 9.37 72.50 ± 5.07 <0.001
60’ P100, ms 108.00 ± 11.76 101.84 ± 6.28 <0.001
15’ P100, ms 108.75 ± 10.22 106.87 ± 8.06 0.287
60’ N135, ms 153.04 ± 18.02 142.68 ± 16.30 <0.001
15’ N135, ms 149.34 ± 16.46 140.78 ± 11.27 <0.001
60’ N135–N75, ms 81.15 ± 18.91 73.75 ± 16.88 <0.001
15’ N135–N75, ms 74.00 ± 19.26 68.28 ± 12.14 0.020
60’ N75–P100, μV 9.13 ± 5.20 10.25 ± 6.71 0.344
15’ N75–P100, μV 8.68 ± 5.00 12.52 ± 9.32 0.332
60’ P100–N135, μV 10.39 ± 5.99 11.77 ± 5.04 0.069
15’ P100–N135, μV 11.37 ± 6.10 14.04 ± 5.51 <0.001
PERG
N35, ms 31.78 ± 3.57 29.26 ± 1.75 <0.001
P50, ms 54.57 ± 4.72 50.85 ± 2.16 <0.001
N95, ms 96.04 ± 9.28 91.48 ± 5.17 <0.001
N35–P50, μV 5.55 ± 2.46 3.86 ± 0.99 0.532
P50–N95, μV 7.22 ± 3.16 5.33 ± 1.44 <0.001
PERG ratio 1.40 ± 0.40 1.40 ± 0.23 <0.001
RCT 60’ (P100–P50), ms 53.43 ± 12.82 50.87 ± 6.96 0.519
RCT 15’ (P100–P50), ms 54.18 ± 11.11 55.90 ± 8.56 0.161
 Values represent mean ± SD. 15’ and 60’ refer to the checksizes 
used for stimulation. RCT = Retinocortical time.
 Table 2.  Alterations of the VEP and PERG values in the polyneu-
ropathy-free group as compared to the reference values of the lab-
oratory
Patient Reference p value 
VEP
60’ N75, ms 70.42 ± 10.02 68.93 ± 5.53 0.728
15’ N75, ms 75.02 ± 12.97 72.50 ± 5.07 0.231
60’ P100, ms 105.06 ± 11.96 101.84 ± 6.28 0.206
15’ P100, ms 109.21 ± 11.22 106.87 ± 8.06 0.207
60’ N135, ms 146.23 ± 16.87 142.68 ± 16.3 0.202
15’ N135, ms 152.29 ± 20.46 140.78 ± 11.27 <0.001
60’ N135–N75, ms 75.81 ± 20.49 73.75 ± 16.88 0.686
15’ N135–N75, ms 76.40 ± 21.19 68.28 ± 12.14 0.040
60’ N75–P100, μV 6.74 ± 3.65 10.25 ± 6.71 <0.001
15’ N75–P100, μV 6.80 ± 3.84 12.52 ± 9.33 <0.001
60’ P100–N135, μV 7.18 ± 5.0 11.77 ± 5.04 <0.001
15’ P100–N135, μV 8.33 ± 5.19 14.04 ± 5.51 <0.001
PERG
N35, ms 32.77 ± 3.66 29.26 ± 1.75 <0.001
P50, ms 55.81 ± 4.65 50.85 ± 2.16 <0.001
N95, ms 100.1 ± 8.36 91.48 ± 5.17 <0.001
N35–P50, μV 3.99 ± 1.98 3.86 ± 0.99 0.501
P50–N95, μV 5.53 ± 2.54 5.33 ± 1.44 0.272
PERG ratio 1.51 ± 0.54 1.40 ± 0.23 0.720
RCT 60’ (P100–P50), ms 49.25 ± 12.56 50.87 ± 6.96 0.433
RCT 15’ (P100–P50), ms 53.4 ± 10.99 55.90 ± 8.56 0.263
 Values represent mean ± SD. 15’ and 60’ refer to the checksizes 
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level (0.05), and n is the number of independent comparisons. The 
adjusted level of significance was p = 0.01. Statistical analyses were 
conducted in SPSS 21.0 (IBM, USA). 
 For stimulation and recording, a Roland Electrophysiological 
Test Unit was used, with the RETIport 32 software (Roland Con-
sult, Brandenburg an der Havel, Germany). Before the tests, the 
refractive errors of the eyes were determined and corrected for 
viewing distance.
Statement of Ethics
 The study was designed according to the Declaration of Hel-
sinki, and it was approved by the Biomedical Research Ethics 
Committee of the University of Szeged. All patients were informed 
that their medical data would be used for research purposes, and 
written informed consent was requested from all the 63 patients. 
Data were used only upon consent.
 Results 
 The mean age in the polyneuropathy group was 47.4 
years (range: 20–74 years). The mean diabetes duration 
in this group was 15.2 years (range: 1–40 years). The 
mean age of the polyneuropathy-free group was 49.1 
years (range: 21–74 years). The mean diabetes duration 
in this group was 14.9 years (range: 1–40 years).
 In the polyneuropathy group, VEP was abnormal in 76 
(100%) eyes, and this was accompanied by PERG altera-
tions in half of the cases, while in the polyneuropathy-free 
group, VEP was abnormal in 40 eyes accompanied by ab-
normal PERG in 38 (95%) eyes. Normal electrophysio-
logical responses were not found in the polyneuropathy 
group, while in the polyneuropathy-free group normal 
responses were recorded from 10 (20%) eyes. Examples 
of the characteristic alterations are shown in  figure 1 . In 
the polyneuropathy group, the leading alteration was an 
abnormal delay of P100 which was seen in 62 (82%) eyes. 
Doubled P100 peaks and abnormally broad waveforms 
were also observed but only sporadically (doubled peaks 
in 6 eyes and broad waveforms in 8 eyes).
 PERG findings were abnormal in 38 (50%) eyes. Of the 
76 eyes, P50 peak time was delayed in 28 (37%) eyes, and 

















 Fig. 1. Characteristic waveform alterations that are seen already 
when neither polyneuropathy nor the vascular form of retinal in-
volvement is detectable. Recordings from 6 eyes of 6 different pa-
tients from the nonpolyneuropathy group. VEP alterations: in-
creased P100 latency in both the 60’ and 15’ conditions, and a 
markedly subnormal P100 response in the 15’ condition ( a ); broad 
waveforms in both stimulation conditions ( b ); double P100 peaks 
in both stimulation conditions ( c ). PERG alterations: increased 
P50 and N95 latency (an elongated response) ( d ); markedly sub-
normal P50 response ( e ); selective N95 attenuation ( f ). The altera-
tions are indicated by arrows. Calibration: amplitude (abscissa) 
5 μV/division; time (ordinate) 25 ms/division. The analytically 
 important peaks and troughs are indicated by crosses. Other con-


















   
   
   
   
   
   
   
   
   
   

























peak-to-peak amplitudes were found (21%). The depres-
sion of the N95 amplitude was particularly characteristic 
( table 1 ).
 In the polyneuropathy-free group, the most frequently 
observed alteration was also an abnormal P100 delay 
which was seen in 21 (42%) eyes. As for the most frequent 
PERG abnormalities in this group, P50 peak time was de-
layed in 24 (48%) eyes, and subnormal P50 and N95 am-
plitudes were found in 11 (22%) eyes ( table 2 ).
 Discussion 
 In this study, the VEP and PERG were sensitive indica-
tors of subclinical retinal and optic nerve involvement in 
diabetes even at an early stage when the patients were free 
of neuropathy and the fundus showed no signs of retinal 
involvement. These methods are also less time-consum-
ing than normal and multifocal ERGs that require dark 
adaptation and pupil dilation  [13] . Equally important, 
PERG and VEP are best used in combination for the pur-
poses of ophthalmological screening in diabetes. Given 
the continuity of the optic nerve with the retina, an ab-
normal VEP recording could indicate either optic neu-
ropathy or retinopathy or both. This differential diagnos-
tic problem would be resolved by the simultaneous use of 
electroretinography.
 As for the specific abnormalities found in this study, 
especially the peak delays and subnormal responses ap-
pear to be characteristic of the studied diabetic patient 
populations, while less frequent alterations, like double 
P100 peaks, definitely require further corroboration. 
However, it must be taken into consideration that the aim 
of this study was not to categorize the alterations that can 
be found early in the course of disease progression, but to 
investigate if they can be found at all. Our results show 
that the alterations can be detected, and we suggest that 
the qualitative details be considered as data to be con-
firmed or disproven by later studies.
 Conclusions 
 Our findings showed that PERG and VEP were sensi-
tive tools for the early detection of neural damage, well 
before the retinal involvement becomes evident on fun-
doscopy. Therefore, we suggest that regular electrophysi-
ological screening should receive more attention in the 
ophthalmological care of diabetic patients with the diag-
nosis of the disease.
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